Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Recursion Pharmaceuticals RXRX stock surged 16% in early October 2025 on renewed AI interest despite posting $171.9 million ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
JetBrains’ latest State of Developer Ecosystem report shows Microsoft’s TypeScript leading the firm’s “Promise Index,” a ...
We recently published 10 Stocks Stealing Today’s Spotlight; 5 on All-Time Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ...
Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 45,210 calls trading, 6x expected, and implied vol increasing over 39 points ...
Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated at ...
We are actively working to enhance your experience by translating more content. However, please be aware that the page you are about to visit has not yet been translated. We appreciate your ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results